Literature DB >> 15992991

Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.

Luca Puccetti1, Claudiu T Supuran, Pier P Fasolo, Enrico Conti, Giancarlo Sebastiani, Sergio Lacquaniti, Roberto Mandras, Maria G Milazzo, Natalia Dogliani, Paolo De Giuli, Giuseppe Fasolis.   

Abstract

OBJECTIVE: The prognostic influence of neuroendocrine (NE) differentiation in prostate cancer patients is not yet properly established. In a series of primary hormone-naive prostate cancers from a patient population that underwent radical prostatectomy, we wanted to determine the relationship between NE phenotype expression and Gleason sum, disease stage, and serum PSA concentration.
METHODS: Chromogranin A (CgA) expression was scored and compared in 105 consecutive primary prostate cancers with their homologous preoperative tumor prostate biopsies.
RESULTS: High grade or high stage prostate cancers expressed a significantly higher CgA score than low grade or localized diseases (p < 0.005). Both the CgA score of the surgical specimens and the PSA level in the serum increased linearly (p = 0.001). In the samples of many corresponding tumor biopsies no significant CgA staining was found.
CONCLUSION: NE differentiation in primary untreated prostate cancer is closely associated with the major prognostic parameters of survival. This association cannot be shown by evaluating the CgA staining in tumor biopsies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15992991     DOI: 10.1016/j.eururo.2005.03.018

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

Review 1.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

2.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma.

Authors:  Lawrence True; Ilsa Coleman; Sarah Hawley; Ching-Ying Huang; David Gifford; Roger Coleman; Tomasz M Beer; Edward Gelmann; Milton Datta; Elahe Mostaghel; Beatrice Knudsen; Paul Lange; Robert Vessella; Daniel Lin; Leroy Hood; Peter S Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-07       Impact factor: 11.205

3.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

Review 4.  Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.

Authors:  David S Priemer; Rodolfo Montironi; Lisha Wang; Sean R Williamson; Antonio Lopez-Beltran; Liang Cheng
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

Review 5.  Molecular Imaging of Prostate Cancer.

Authors:  Andreas G Wibmer; Irene A Burger; Evis Sala; Hedvig Hricak; Wolfgang A Weber; Hebert Alberto Vargas
Journal:  Radiographics       Date:  2015-11-20       Impact factor: 5.333

Review 6.  Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?

Authors:  Alexandru Dan Grigore; Eshel Ben-Jacob; Mary C Farach-Carson
Journal:  Front Oncol       Date:  2015-03-03       Impact factor: 6.244

Review 7.  Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle.

Authors:  Alfredo Berruti; Francesca Vignani; Lucianna Russo; Valentina Bertaglia; Mattia Tullio; Marcello Tucci; Massimiliano Poggio; Luigi Dogliotti
Journal:  Open Access J Urol       Date:  2010-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.